Background
Multipurpose prevention technologies (MPTs) are important to protect women from unintended pregnancy and sexually transmitted infections. Uniquely designed, geometrically complex 3D printed intravaginal rings (IVRs) represent an attractive long-acting delivery platform that can provide superior control of drug release and product user characteristics. To optimize the delivery of Islatravir (ISL) within our MPT IVR delivering ISL in combination with ethinyl estradiol and etonogestrel, IVRs containing 15, 30, and 60 mg of ISL were evaluated for their pharmacokinetics (PK) in pigtailed macaques. We further investigated the efficacy of a 60 mg, 90-day ISL IVR against vaginal SHIV infection in macaques.
Methods
IVRs containing 15, 30, and 60 mg ISL were inserted for 28 days into pigtailed macaques (n=8) in a crossover design. The 15 and 60 mg ISL IVRs were subsequently investigated for 90-day PK studies (n=3 macaques each). Plasma, PBMC, and mucosal fluid were collected for drug quantitation by AB Sciex API-5000 triple quadruple mass spectrometer. Based on the total amount of ISL released over the 90-day period, we initiated a vaginal SHIV challenge study in sexually mature, normal cycling pigtailed macaques (n=8). Six ISL (60 mg) IVR-treated macaques received weekly SHIV162p3 inoculations starting 3 days after IVR insertion. Two untreated controls received the same weekly challenges. Infection was monitored by RT-PCR.
Results
Systemic ISL concentrations were within the levels seen with the safe 0.25 mg once-daily oral human dose (Table). It was determined that the 15 mg rings released 94% of ISL over 90 days while the 60 mg had released 56%. The 60 mg IVR maintained ISL triphosphate (ISL-TP) at or above established ISL-TP benchmark concentration needed for protection (50 fmol/106 cells) for over 90 days and was investigated for its efficacy against vaginal SHIV infection. All ISL IVR-treated macaques remain SHIV RNA negative after 8 weekly SHIV challenges while the two controls became infected at 2 and 3 exposures.
Conclusions
We demonstrate that a 60 mg 3D-printed ISL IVR provides sustained vaginal release of ISL over 90 days and results in systemic ISL dosing. Systemic ISL concentration remained below the clinical toxicity threshold and prevented SHIV acquisition in macaques. These results warrant further development of the 3D printed IVR as a three-month MPT for prevention of HIV and unintended pregnancy using an already optimized hormones dose.